ReviewCancers2022
Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Could Subjective Cognitive Complaints Give the Facts of Objective Cognitive Impairments in Non-Central Nervous System Cancer? A Systematic Review.Brain and behavior · 2026Pooled it
- Cognitive impairment following breast cancer treatments: an umbrella review.The oncologist · 2024Pooled it
- Links between nocturnal hypoxia and cognitive function in breast cancer.Scientific reports · 2025Trial
- Trial
- Cancer-related cognitive impairment in adult cancer survivors: a clinical practice review for healthcare providers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess.Frontiers in pharmacology · 2026Article
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study.Breast cancer research and treatment · 2025Article
- Long-term health-related quality of life among adolescent and young adult breast cancer survivors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Unveiling Cognitive Impairment in Older Adults with Cancer on Systemic Anticancer Therapy: A Comprehensive Review.Drugs & aging · 2025Review
- Computerized cognitive training improves cognitive function in primary breast cancer survivors.NPJ breast cancer · 2024Article
- Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer.JAMA network open · 2024Article
- Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.Scientific reports · 2024Article
- Relationship of physical activity and cognitive functioning among breast cancer survivors: a cross-sectional analysis.Frontiers in cognition · 2024Article
- Article
- Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?JNCI cancer spectrum · 2023Article
- Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer.JNCI cancer spectrum · 2023Article
- Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.Frontiers in pharmacology · 2023Article
- A novel oncogenic enhancer of estrogen receptor-positive breast cancer.Molecular therapy. Nucleic acids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine therapy forms the backbone of systemic therapy for the majority of persons with early and late-stage breast cancer. However, the side effects can negatively affect quality of life, and impact treatment adherence and overall oncological outcomes. Adverse effects on cognition are common, underreported and challenging to manage. We aim to describe the nature, incidence, risk factors and underlying mechanisms of endocrine therapy-induced cognitive dysfunction. We conducted a comprehensive literature review of the studies reporting on cognitive dysfunction associated with endocrine therapies for breast cancer. We also summarise prevention and treatment strategies, and ongoing research. Given that patients are taking endocrine therapies for longer durations than ever before, it is essential that these side effects are managed pro-actively within a multi-disciplinary team in order to promote adherence to endocrine therapy and improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.